Aging lies at the core of every age-related disease
and affects every person on the planet. It represents an unbearable toll
on the economies of the developed countries resulting in over two
trillion dollars in direct medical costs, costs of caring and lost
productivity in the US and EU alone. Yet, pharmaceutical companies fail
to see the practical applications of aging research as many early
experiments with drugs that held promise in slowing the aging processes
resulted in commercial failures and write offs. Lack of business models,
regulation and absence of a clear set of aging biomarkers make it
difficult for large pharmaceutical companies to fully engage in aging
research. Unlike other events that are geared towards academia or have a
broad range of topics, this forum intends to focus on drug discovery
and pharmaceuticals that may have a role in postponing the aging
processes, preventing the age-related diseases and evaluating the
effectiveness of various small molecules with geroprotective properties.
The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field:
Session I: Practical approaches to aging research: aging biomarkers and big data analysis
Chair: Georg Fullen
Session II: Geroprotective drugs: drug repurposing, in silico screening and rational drug design
Chair: Alexey Moskalev
Please visit the website www.AgingPharma.org for further information.
Please subscribe to our Newsletter so stay informed about the latest updates.
No comments:
Post a Comment